Many challenges will have to be faced in the next decade to bring more efficient and affordable antibody-based drugs to the clinic. Here, we discuss strategies to select the best therapeutic ...

South Korea's DAAN Biotherapeutics has entered an exclusive deal with LigaChem Biosciences to develop a novel tumor-targeting ...

Building on these advances, antibody drug conjugate (ADC) therapy has emerged with worldwide marketing approvals for the indications of breast cancer and lymphoma. An ADC is divided into three ...

The whole P-cadherin/antibody/drug complex is then sent to a structure called the lysosome to be broken down. “Our results establish an outside-in signaling mechanism that provides fundamental ...

New York, United States, Jan. 22, 2025 (GLOBE NEWSWIRE) -- ADCs, or antibody-drug conjugates, are chemotherapeutic agents explicitly designed to treat cancer cells. Antibody-drug conjugates ...

ABBV-154, an antibody-drug conjugate comprising adalimumab conjugated to a proprietary glucocorticoid receptor modulator, shows potential for extending flare-free periods in patients with ...

The antibody delivers a drug package and activates the immune system for tailored immunotherapy treatments. It specifically redirects the immune system to recognise and attack ‘neoantigens ...

The most advanced, I will say, have to be antibody drug conjugates. At least two of them. One is a HER3 ADC. The other is a TROP2 ADC, has show excellent preliminary data. Potentially can be ...

UK-based Ellipses Pharma, a company progressing cancer treatments through an innovative drug development model, has announced that it is to develop a next-generation immuno-oncology drug which could ...

Exclusive global license outside of Greater China for MRG007, a novel antibody drug conjugate (ADC) in development for gastrointestinal (GI) cancers First Investigational New Drug (IND ...